Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 04 May 2021
TGA approves new treatment for aggressive form of prostate cancer
5 May 2021 - The TGA has registered a new medication to treat a particularly aggressive and advanced type of ...
Posted by Michael Wonder on 04 May 2021
ViiV Healthcare initiates rolling submission of new drug application with US FDA for long-acting cabotegravir for prevention of HIV
4 May 2021 - If approved, cabotegravir would be the first, long-acting therapy for HIV PrEP. ...
Posted by Michael Wonder on 04 May 2021
Australia's TGA grants approval to first objective concussion diagnostic
4 May 2021 - Oculogica's EyeBOX is the only objective diagnostic cleared by the US FDA and Australia TGA as an ...
Posted by Michael Wonder on 04 May 2021
Micro Medical Solutions receives FDA breakthrough device designation for MicroStent vascular stent
4 May 2021 - Breakthrough designation helps advance treatment options, targeting a significant unmet need in the treatment of critical limb-threatening ischaemia. ...
Posted by Michael Wonder on 04 May 2021
Uncertain effect and high prices of precision medicine are challenging
3 May 2021 - In a report to the government, the Swedish Dental and Pharmaceutical Benefits Agency, TLV, describes the most ...
Posted by Michael Wonder on 04 May 2021
SIGA announces new drug application filing with FDA for intravenous formulation of TPOXX
4 May 2021 - Important for patients who cannot swallow oral capsules. ...
Posted by Michael Wonder on 04 May 2021
NICE announces more people eligible for nusinersen sodium following review of Managed Access Agreement
4 May 2021 - NICE has today announced that more people with the rare genetic disorder spinal muscular atrophy are to ...
Posted by Michael Wonder on 04 May 2021
EMA starts rolling review of COVID-19 vaccine (Vero Cell) inactivated
4 May 2021 - EMA’s CHMP has started a rolling review of COVID-19 Vaccine (Vero Cell) inactivated, developed by Sinovac ...
Posted by Michael Wonder on 04 May 2021
Clearside Biomedical announces resubmission of new drug application for Xipere for treatment of macular oedema associated with uveitis
3 May 2021 - Clearside Biomedical announced today the resubmission of its new drug application to the U.S. FDA for ...
Posted by Michael Wonder on 04 May 2021
Astellas' Xtandi (enzalutamide) approved by European Commission for men with metastatic hormone sensitive prostate cancer
4 May 2021 - Enzalutamide is now the only oral therapy approved by the European Commission to treat three distinct types ...
Posted by Michael Wonder on 04 May 2021
Diabetes drugs: list price increases were not always reflected in net price; impact of brand competition unclear
3 May 2021 - List prices for brand-name drugs have risen steeply, often despite the introduction of competition from other brand-name ...
Posted by Michael Wonder on 04 May 2021
Andrew Little not pleased with Children's Commissioner comments on potential PHARMAC move
4 May 2021 - Heath Minister Andrew Little says he expects better of the Children's Commissioner after he described a potential ...
Posted by Michael Wonder on 03 May 2021
Doubt over local mRNA plans as major companies pull out of Australia
3 May 2021 - Vaccine development experts say it will take at least $250 million plus the support of a ...
Posted by Michael Wonder on 03 May 2021
Amphastar Pharmaceuticals receives FDA approval for morphine sulphate injection
3 May 2021 - Amphastar Pharmaceuticals announced that the U.S. FDA approved the Company’s abbreviated new drug application for morphine sulphate ...
Posted by Michael Wonder on 03 May 2021
TLV reconsiders subsidy for eleven TNF alfa inhibitors included in the high-cost protection
30 April 2021 - Today, eleven subcutaneous TNF-alpha inhibitors are included in the high-cost protection. ...